Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

In This Article:

The healthcare sector continues to advance with technological breakthroughs and growing demand for medical services, creating opportunities for strong earnings growth in 2025 and beyond. With rising healthcare expenditures, an aging population and increasing disease prevalence, investors seeking growth can consider stocks with expanding margins in the medical space.

As 2025 progresses, the sector faces both opportunities and headwinds. While demographic trends and medical innovation support long-term growth, challenges such as potential government spending cuts, reduced funding and the expiration of insurance subsidies create uncertainty. Despite these hurdles, companies like Gilead Sciences, Inc. GILD, Option Care Health, Inc. OPCH and Aveanna Healthcare Holdings Inc. AVAH stand out as compelling picks. These companies have demonstrated resilience with impressive earnings surprise history, positioning them as attractive buys at the current levels for investors seeking potential long-term gains in this dynamic industry.

1-Year Price Performance – GILD, OPCH, AVAH, Medical Sector & S&P 500

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Let’s take a closer look at these three healthcare stocks and why they stand out.

Gilead Sciences: GILD is a dominant player in the HIV market, being the first to bring a single-tablet regimen to the market for its treatment and grab a formidable market share. Based in Foster City, CA, its efforts to bolster its oncology and virology franchises through internal pipeline development and collaborations are commendable.

Trading close to its 52-week high of $117.39 a share and with 14.55X forward earnings, Gilead Sciences stock remains well below its industry average of 45.36X. The life-saving drug-developing giant has a Value Score of B at present.

The company currently has a Zacks Rank #2 (Buy) and a VGM Score of A. Our research shows that stocks with a VGM Score of A or B, combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best investment opportunities for investors. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for GILD’s 2025 earnings is pegged at $7.86 per share, indicating 70.1% year-over-year growth. The estimate witnessed nine upward estimate revisions over the past month against only two movements in the opposite direction. Its 2026 earnings estimate indicates a further 5.1% increase. The consensus mark for 2025 revenues is pegged at $28.55 billion, while the same for 2026 suggests a 4% year-over-year increase.